Home
Syncom Formulations (india) Ltd EPS

Syncom Formulations (India) Ltd
NSE: SYNCOMFORMUL
EPS
Key Highlights
- The Earning per Share of Syncom Formulations (India) Ltd is ₹ 0.42 as of 21 Feb 25 .
- The earning per share of Syncom Formulations (India) Ltd changed from ₹ 0.07 to ₹ 0.14 over 7 quarters. This represents a CAGR of 48.60% .
Historical Earning per Share of Syncom Formulations (India) Ltd
EPS, or Earnings Per Share, is a financial metric that represents the portion of a company's profit allocated to each outstanding share of common stock. It indicates a company's profitability and is calculated by dividing net income by the number of outstanding shares.
Historical Earning per Share of Syncom Formulations (India) Ltd
Company Fundamentals for Syncom Formulations (India) Ltd
Market Cap
1,598 Cr
EPS
0.4
P/E Ratio (TTM)
40.5
P/B Ratio (TTM)
5.1
Day’s High
17.7
Day’s Low
16.96
DTE
0.0
ROE
10.6
52 Week High
27.94
52 Week Low
11.0
ROCE
14.3
Market Price of Syncom Formulations (India) Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
21 Feb 2025 | 17 |
20 Feb 2025 | 17.33 |
19 Feb 2025 | 17.01 |
18 Feb 2025 | 16.67 |
17 Feb 2025 | 17.16 |
14 Feb 2025 | 17.57 |
13 Feb 2025 | 18.04 |
12 Feb 2025 | 18.06 |
11 Feb 2025 | 18.34 |
10 Feb 2025 | 18.01 |
SWOT Analysis Of Syncom Formulations (India) Ltd
BlinkX Score for Syncom Formulations (India) Ltd
Asset Value vs Market Value of Syncom Formulations (India) Ltd
Market Value
₹ 1,598
Asset Value
Value addition
6.5 X
₹ 212
* All values are in ₹ crores
Competitive Comparison of EPS
Company | Market Cap | EPS |
---|
Syncom Formulations (India) Ltd | 1598 | 0.42 |
Sun Pharmaceuticals Industries Ltd | 394223 | 49.16 |
Divis Laboratories Ltd | 152610 | 77.86 |
Cipla Ltd | 119067 | 61.78 |
Torrent Pharmaceuticals Ltd | 102739 | 55.02 |
Dr Reddys Laboratories Ltd | 96124 | 64.37 |
Company | |
---|---|
Syncom Formulations (India) Ltd | 1598 |
Sun Pharmaceuticals Industries Ltd | 394223 |
Divis Laboratories Ltd | 152610 |
Cipla Ltd | 119067 |
Torrent Pharmaceuticals Ltd | 102739 |
Dr Reddys Laboratories Ltd | 96124 |
Historical Market Cap of Syncom Formulations (India) Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Syncom Formulations (India) Ltd
Historical Revenue of Syncom Formulations (India) Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Revenue of Syncom Formulations (India) Ltd
Historical EBITDA of Syncom Formulations (India) Ltd
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Historical EBITDA of Syncom Formulations (India) Ltd
Historical Net Profit of Syncom Formulations (India) Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of Syncom Formulations (India) Ltd
Dividend Payout Over Time
Syncom Formulations (India) Ltd News Hub
Nifty slips below 24,200 level; Nifty bank shares buck trend; HDFC Bank drops 2.93%
The main equity indices traded with significant losses in mid-afternoon trade. The Nifty dropped bel
Read more
13 Aug 24
Syncom Formulations gains after Q1 PAT rises over 73% YoY
Net sales rose by 45.8% year-over-year (YoY) during the quarter to Rs 87.26 crore. Total expenditure
Read more
13 Aug 24
Syncom Formulations (India) consolidated net profit rises 73.41% in the June 2024 quarter
Net profit of Syncom Formulations (India) rose 73.41% to Rs 7.63 crore in the quarter ended June 202
Read more
12 Aug 24
Syncom Formulations (India) announces board meeting date
Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company on 12 Augus
Read more
06 Aug 24